Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 619-447-3 | CAS number: 99607-70-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 02 November 1988 to 12 May 1989
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Fully GLP and test guideline compliant study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 990
- Report date:
- 1990
Materials and methods
- Objective of study:
- absorption
- distribution
- excretion
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 85-1 (Metabolism and Pharmacokinetics)
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes
Test material
- Reference substance name:
- heptan-2-yl [(5-chloroquinolin-8-yl)oxy]acetate
- EC Number:
- 619-447-3
- Cas Number:
- 99607-70-2
- Molecular formula:
- C18H22ClNO3
- IUPAC Name:
- heptan-2-yl [(5-chloroquinolin-8-yl)oxy]acetate
- Details on test material:
- - Name of test material (as cited in study report): CGA185072 (company code)
[14C]- cloquintocet-mexyl
Radiochem. purity:
Specific activity:> 96%. Determined by TLC.
Specific Activity 1940 kBq/mg (52.51 uCi/mg)
For the treatment the test material was diluted with non-labelled material to a specific activity of
1847 kBq/mg (49.93 uCi/mg) - Group B
1501 kBq/mg (40.58 uCi/mg) - Group C
35.3 kBq/mg (0.953 uCi/mg) - Group D
1733 kBq/mg (46.84 uCi/mg) - Group E
34.2 kBq/mg (0.924 uCi/mg) - Group F
Constituent 1
- Radiolabelling:
- yes
- Remarks:
- [14C]- cloquintocet-mexyl
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 6 to 10 weeks
- Weight at study initiation: 160 - 250 g
- Individual metabolism cages: yes for collection of volatiles and expired air
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 7 days
IN-LIFE DATES: From: 02 November 1988 To: 12 May 1989
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: Polyethylene glycol 200/ ethanol/ water 45/25/30 (v/v)
- Details on exposure:
- Dosing groups for pharmacokinetic study with cloquintocet-mexyl - see table below
- Duration and frequency of treatment / exposure:
- Single or repeat
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0.5, 100mg/kg
- No. of animals per sex per dose / concentration:
- Groups B-D five males and five females
Groups E and F three males and three females - Control animals:
- no
- Details on dosing and sampling:
- In Groups B to D, urine and faeces were collected 6, 12 and 24 hours after dosing and thereafter at 24 hours intervals over 7 days. At the end of the collection period, cages were rinsed with methanol/water and the cage wash solution was sampled. Volatiles and expired air were collected after 6, 12 and 24 hours. At sacrifice, blood was collected and the following tissues and organs were taken: Adrenals, bone, bone marrow, brain, fat (abdominal), gonads, heart, kidneys, liver, lung, uterus, skeletal muscle, spleen, thymus, thyroid, residual carcass.
In the biliary excretion groups E and F, the rats were canulated and allowed to recover for 24 hours before administration of the test substance. Urine and faeces were collected after 24 and 48 hours and bile was collected after 1, 2, 4, 8, 24 and 48 hours
Radioactivity was measured by scintillation counting using standard methods and scintillation mixes. In addition, pooled samples from urine, faeces (and bile in groups E and F) were sent to the sponsor for chromatographic characterization of the metabolite profile. - Statistics:
- Not specified
Results and discussion
- Preliminary studies:
- Clinical assessment of Groups B to F
During the observation period in Groups B, C and D there were no signs of toxicity. Among the bile canulated animals, all three high dose (Group F) females died between 12 and 48 hours after the administration. The cases were attributed to stress and are not considered to be a toxic effect of the test article.
Main ADME resultsopen allclose all
- Type:
- absorption
- Results:
- Radioactivity in urine and bile accounted for at least 40% of the dose.
- Type:
- distribution
- Results:
- Seven days after treatment with 0.5 mg/kg or 100 mg/kg cloquintocet-mexyl residues were below the detection limit in all tissues. Also pretreatment with the non-labelled test material did not lead to detectable residues in individual organs
- Type:
- excretion
- Results:
- No radioactivity was detected in expired air. Approximately 30% of the dose was excreted in urine with the remainder in faeces. Biliary secretion accounted for approximately 15% of the dose. The route and rate of excretion was independant of the dose.
Metabolite characterisation studies
- Metabolites identified:
- no
Any other information on results incl. tables
Excretion kinetics in rats after oral gavage of 14C-CGA 185072 (Excretion of radioactivity in % of the administered dose)
Group |
B |
C |
D |
|||
Dose mg/kg bw |
0.53 |
0.51 |
0.50 |
0.50 |
99.2 |
99.2 |
Sex |
Males |
Females |
Males |
Females |
Males |
Females |
Urine Subtotal |
|
|
|
|
|
|
Faeces 0 - 24 hrs Subtotal |
55.0 |
|
|
|
|
|
Expired air |
ND |
ND |
ND |
ND |
ND |
ND |
Tissues + carcass |
0.4 |
ND |
0.1 |
ND |
0.1 |
ND |
Cage wash |
5.6 |
8.5 |
14.3 |
5.5 |
4.6 |
7.6 |
Total Excretion |
87.6 |
94.3 |
88.3 |
88.6 |
93.4 |
98.5 |
Total Recovery |
88.0 |
94.3 |
88.3 |
88.6 |
93.4 |
98.5 |
Biliary excretion in rats after oral gavage of 14C-CGA 185072 (Excretion of radioactivity in % of the administered dose)
Group |
E |
F |
||||||
Dose mg/kg bw |
0.52 |
0.55 |
99.1 |
93.5
|
||||
Sex |
Males |
Females |
Males |
Females
|
||||
Bile |
|
|
|
|
|
|||
Urine |
|
|
|
|
|
|||
Faeces Subtotal (48 hrs) |
|
|
|
|
|
|||
Tissues + carcass |
0.5 |
2.3 |
1.1 |
57.1 |
|
|||
Cage wash |
4.4 |
4.3 |
7.0 |
1.6 |
|
|||
Total Excretion |
82.3 |
83.3 |
94.0 |
28.2 |
|
|||
Total Recovery |
86.7 |
85.6 |
95.1 |
85.3 |
|
|||
The apparently low excretion in the females is due to the premature death of all three individuals |
|
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): no bioaccumulation potential based on study results
The test compound was rapidly absorbed and excreted. The main portion of the radioactivity was excreted within 24 hours after the dosing with urine and faeces. Urinary and biliary excretion revealed that at least 50% of the orally administered test material were absorbed from the intestinal tract in both sexes. The compound did not accumulate in any tissue or organ. - Executive summary:
Radiolablled test material was administered to groups of rats as a single or repeated oral administration or to bile-cannulated animals in five separate assays, in accordance with EPA test methods. Samples were collected for determination of excretion via expired air, urine and faeces and biliary excretion. Radioactivity recovery and tissue absorption values were determined. Blood, tissues, organs and residual carcass were analysed for absorption and distribution. There were no signs of systemic toxicity. Deaths among the bile-cannulation groups were attributed to procedural stress rather than toxic effects of treatment. The test compound was rapidly absorbed and excreted. The main portion of the radioactivity was excreted within 24 hours after the dosing with urine and faeces. Urinary and biliary excretion revealed that at least 40% of the orally administered test material were absorbed from the intestinal tract in both sexes. The compound did not accumulate in any tissue or organ. Calculated from urinary and biliary excretion and tissue residues, around 50% of an orally administered dose were absorbed into general circulation by both sexes and at both dose levels. Excretion was essentially complete within 48 hours. Independent from sex or dose around 60% of the administered radioactivity were found in the faeces and 40% in the urine. Biliary excretion amounted to 15%. No radioactivity was detected in the expired air, indicating that the quinoline ring of the molecule was not broken down during metabolization. Pretreatment with non-labelled test material did not alter the kinetics of cloquintocet-mexyl.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.